Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS).
We seek to deliver transformative therapies to patients by leveraging our team’s decades of experience, including our founders, as well as the transformative potential genetic medicine technology to develop treatments that improve outcomes for patients with serious, life-threatening, rare CNS disorders.
Critical to this strategy is what we believe to be a differentiated approach to genetic medicine development via our collaboration with Penn’s GTP and Orphan Disease Center, led by our co-founder and Chief Scientific Advisor Dr. James Wilson.
In addition to our strategy, we have recruited, beginning with our founders, Dr. Squinto, Dr. Wilson and Dr. Yamada, a world class team of leaders who have decades of experience in working in, creating and successfully growing rare disease, central nervous disorders and gene therapy focused companies.
We have assembled a deep pipeline of genetic medicine product candidates, including our three lead product candidates: PBGM01 for the treatment of GM1 gangliosidosis (GM1), PBFT02 for the treatment of frontotemporal dementia (FTD) and PBKR03 for the treatment of Krabbe disease.
We seek to deliver transformative therapies to patients by leveraging our team’s decades of experience, including our founders, as well as the transformative potential genetic medicine technology to develop treatments that improve outcomes for patients with serious, life-threatening, rare CNS disorders.
Critical to this strategy is what we believe to be a differentiated approach to genetic medicine development via our collaboration with Penn’s GTP and Orphan Disease Center, led by our co-founder and Chief Scientific Advisor Dr. James Wilson.
In addition to our strategy, we have recruited, beginning with our founders, Dr. Squinto, Dr. Wilson and Dr. Yamada, a world class team of leaders who have decades of experience in working in, creating and successfully growing rare disease, central nervous disorders and gene therapy focused companies.
We have assembled a deep pipeline of genetic medicine product candidates, including our three lead product candidates: PBGM01 for the treatment of GM1 gangliosidosis (GM1), PBFT02 for the treatment of frontotemporal dementia (FTD) and PBKR03 for the treatment of Krabbe disease.
Location: United States, Pennsylvania, Philadelphia
Employees: 51-200
Total raised: $226M
Founded date: 2018
Investors 5
| Date | Name | Website |
| - | Logos Capi... | logoscapit... |
| - | Access Bio... | accessbio-... |
| - | OrbiMed | orbimed.co... |
| - | Frazier Li... | frazierls.... |
| - | Vivo Capit... | vivocapita... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.09.2019 | Series B | $110M | - |
| 14.02.2019 | Series A | $116M | - |
Mentions in press and media 11
| Date | Title | Description |
| 05.03.2024 | Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program | - |
| 06.10.2021 | Passage Bio : Announces Pennsylvania Scholars Program to Honor Legacy of Biopharma Pioneer Dr. Tachi Yamada | October 6, 2021 Download(opens in new window) Philadelphia, PA - October 6, 2021 - Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) ... |
| 09.03.2021 | How Covid-19 is changing rare diseases research | Twenty years after researchers published their first discoveries associated with human genome sequencing, policymakers are fighting to overcome obstacles that hobble the potential of genetic medicine to recognize, diagnose and cure rare dis... |
| 27.09.2019 | NASH hopeful Genfit promotes Dean Hum to president; Immune Therapeutics CEO passes baton to successor | In 1999, while Dean Hum was an associate professor at Laval University in Quebec, Genfit reached out to him. An expert in the modulation of transcription factors and nuclear receptors associated with endocrine and ca... |
| 04.09.2019 | Plotting clinical entry, James Wilson's gene therapy startup brings in billionaire for $110M Series B | James Wilson The gene therapy biotech that James Wilson helped found to take some rare disease programs out of Penn all the way to an approval has scored $110 million in its latest financing. Passage Bio is getting a boost just... |
| 04.09.2019 | Passage Bio Closes $110 Million Series B Financing | - |
| 04.09.2019 | Passage Bio Closes $110 Million Series B Financing | PHILADELPHIA, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous system (CNS) diseases, today announced the closing of a $1... |
| 14.02.2019 | Passage Bio Founded With $116 million financing, led by OrbiMed | - |
| 14.02.2019 | Passage Bio Launches with $115.5 Million Series A | PHILADELPHIA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Passage Bio today debuted with a $115.5 million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital ... |
| 14.02.2019 | OrbiMed Advisors Leads $115.5M Series A for Passage Bio | PHILADELPHIA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Passage Bio today debuted with a $115.5 million Series A financing led by OrbiMed Advisors and joined by Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital ... |
Show more